影响食管癌患者生存的一个重要参数是淋巴结是否有转移，淋巴结转移主要由组织学类型和肿瘤浸润深度来决定。然而，受肿瘤的病理学特征、异质性和个体差异的影响，目前食管癌淋巴结的分期系统尚未统一，转移规律尚不完全明确，清扫的范围尚有争论；且食管癌淋巴结分期系统尚不完善，其可能导致对患者病情评估不准确，影响临床医生对患者治疗方式的选择，甚至影响临床试验的结论。因此，有必要对食管癌淋巴结分期进一步优化，以便更好地指导以手术为主的综合治疗决策和评估疗效及判断患者预后。 The status of lymph node metastasis is an important parameter affecting the survival of patients with esophageal carcinoma, which is primarily determined by histological type and the depth of invasion. However, affected by pathological features, heterogeneity and individual differences of tumors, the present staging system of lymph node in esophageal carcinoma has not been unified, the rule of lymph node metastasis remains unclear, and the extent of lymphadenectomy is still controversial. Current lymph node staging system for esophageal carcinoma may be not effective enough, which may lead to inaccurate assessment of the stage and affect the clinicians' choice of treatment modalities, or even affect the conclusions of clinical trials. Therefore, it is essential to optimize the current lymph node staging system for esophageal carcinoma to guide the surgery-based multidisciplinary treatment, and effectively to evaluate the therapeutic effects and predict patients' prognosis.
Abstract
The status of lymph node metastasis is an important parameter affecting the survival of patients with esophageal carcinoma, which is primarily determined by histological type and the depth of invasion. However, affected by pathological features, heterogeneity and individual differences of tumors, the present staging system of lymph node in esophageal carcinoma has not been unified, the rule of lymph node metastasis remains unclear, and the extent of lymphadenectomy is still controversial. Current lymph node staging system for esophageal carcinoma may be not effective enough, which may lead to inaccurate assessment of the stage and affect the clinicians' choice of treatment modalities, or even affect the conclusions of clinical trials. Therefore, it is essential to optimize the current lymph node staging system for esophageal carcinoma to guide the surgery-based multidisciplinary treatment, and effectively to evaluate the therapeutic effects and predict patients' prognosis.
万方数据